LON:VER

Vernalis Share Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
6.17
MA: GBX 6.17
6.17
52-Week Range N/A
Volume11,076 shs
Average Volume1.22 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It is also has licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. In addition, the company is developing V158866, a fatty acid amide hydrolase inhibitor for the treatment of pain; CPI-444, an adenosine A2A receptor antagonist, which is in Phase I/Ib clinical trial to treat patients with various solid tumors; and AUY922, an intravenous Hsp90 inhibitor for treating cancer, as well as CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukemia and myelodysplastic syndrome under Phase II trial. Further, it is developing S55746, a selective Bcl-2 inhibitor that is in Phase I study for the treatment of cancer; V158411 molecule; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc.; Biogen Idec; Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc.; Novartis Pharma AG; Servier Research Group; GlaxoSmithKline plc; Genentech; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.
Vernalis logo

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-118-9380000
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Headlines

2 killed, 3 hurt in Stanislaus County crash
September 8, 2020 |  msn.com
See More Headlines

MarketRank

Overall MarketRank

0.68 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive VER News and Ratings via Email

Sign-up to receive the latest news and ratings for VER and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vernalis (LON:VER) Frequently Asked Questions

What stocks does MarketBeat like better than Vernalis?

Wall Street analysts have given Vernalis a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vernalis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Vernalis' earnings last quarter?

Vernalis plc (LON:VER) issued its quarterly earnings results on Tuesday, September, 12th. The company reported ($4.10) EPS for the quarter, beating analysts' consensus estimates of ($4.50) by $0.40. The business had revenue of $20.79 million for the quarter.
View Vernalis' earnings history
.

Who are Vernalis' key executives?

Vernalis' management team includes the following people:
  • Mr. Ian R. Garland, CEO & Exec. Director (Age 52)
  • Mr. David MacKney, CFO & Exec. Director (Age 50)
  • Ms. Susan Wallcraft, Group Gen. Counsel & Company Sec.
  • Mr. Joseph Canny, VP of Marketing
  • Ms. Donna Radzik, Sr. VP of Pharmaceutical Quality Operations

Who are some of Vernalis' key competitors?

What other stocks do shareholders of Vernalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vernalis investors own include Lloyds Banking Group (LLOY), Filtronic (FTC), Entain PLC (GVC.L) (GVC), Oxford Biomedica (OXB), Rogers (ROG), Assura (AGR), Arsanis (ASNS), Bertrandt Aktiengesellschaft (BDT), BP (BP) and Cummins (CMI).

What is Vernalis' stock symbol?

Vernalis trades on the London Stock Exchange (LON) under the ticker symbol "VER."

How do I buy shares of Vernalis?

Shares of VER and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Vernalis' official website?

The official website for Vernalis is www.vernalis.com.

Where are Vernalis' headquarters?

Vernalis is headquartered at 100 Berkshire Place, Wharfedale Road, WOKINGHAM, RG41 5RD, United Kingdom.

How can I contact Vernalis?

Vernalis' mailing address is 100 Berkshire Place, Wharfedale Road, WOKINGHAM, RG41 5RD, United Kingdom. The company can be reached via phone at +44-118-9380000.


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.